Applied Cells opens CellQuest Research Grant to Accelerate Cutting-edge Multiple Myeloma Research

Summation

  • Applied Cells is thrilled to announce the opening of the CellQuest Grant call to all clinical research scientists with a special interest in multiple myeloma and cell therapy development applications.
  • The company's MARS® Platform offers end-to-end sample preparation solutions for efficient small to large scale cell isolation, including unique solutions for the isolation of plasma cells (CD138+) and stem cells (CD34+), empowering researchers to uncover new insights in multiple myeloma and stem cell research.
  • The prize includes a six-month placement of the MARS Bar instrument, supply of cell isolation reagents and consumables, comprehensive training, application development support, and ongoing assistance from a dedicated application scientist.

Applied Cells is thrilled to announce the opening of the CellQuest Grant call to all clinical research scientists with a special interest in multiple myeloma and cell therapy development applications. This remarkable initiative, available until mid-November 2023, offers the opportunity to win a six-month placement of the company’s propriety MARS® Bar cell separation instrument, along with necessary reagents, training and assistance. The collaborative program aims to support exceptional research projects with top-of-the-range cell separation technologies, helping to accelerate our understanding of multiple myeloma and propel the fight against the disease.

This exciting award package offers unparalleled access to the company’s proprietary MARS Bar platform, which uses automated immunomagnetic separation to enrich target cells with high recovery, high purity and high reproducibility. The prize includes a six-month placement of the MARS Bar instrument, supply of cell isolation reagents and consumables, comprehensive training, application development support, and ongoing assistance from a dedicated application scientist.

Applied Cells is excited to invite researchers from around the globe to submit proposals that align with four distinct research areas.

Deciphering the disease: exploring the microenvironment of bone marrow in multiple myeloma.

Focusing on diagnostics: understanding circulating tumor cells in multiple myeloma.

Advancing treatment: tailored approaches for multiple myeloma therapy.
Improving cell therapy: improving protocols for cell-based interventions for multiple myeloma.

Applicants can learn more and apply at https://appliedcells.com/grant-2023/.

Researchers interested in finding out more can connect with Liping Yu, Vice President of Applications at Applied Cells, at the 20th IMS Annual Meeting, September 27-30, to discuss this incredible grant opportunity. Click here to book a meeting with Liping or schedule a call with an Applied Cells representative today.

About Applied Cells
Founded in Silicon Valley, Applied Cells is supporting industry experts across the globe in target cell isolation, cell therapy development and tumor detection. The company’s MARS® Platform offers end-to-end sample preparation solutions for efficient small to large scale cell isolation, including unique solutions for the isolation of plasma cells (CD138+) and stem cells (CD34+), empowering researchers to uncover new insights in multiple myeloma and stem cell research. This streamlined approach saves valuable time by eliminating time-consuming pre-processing steps. Supporting various sample types – including peripheral blood, cord blood, and bone marrow – Applied Cells provides reagents designed to enhance the isolation process, simplifying experimental procedures and increasing overall efficiency.

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy